At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
Location: France, Bourgogne-Franche-Comté, Dijon
Employees: 11-50
Total raised: $26.89M
Founded date: 2016
Investors 4
| Date | Name | Website |
| 10.08.2023 | Crescent E... | crescenten... |
| - | Auriga Par... | auriga.vc |
| - | Capital Gr... | capitalgra... |
| - | Elaia Part... | elaia.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.07.2023 | Series A | $26.89M | - |
Mentions in press and media 8
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| 04.12.2025 | Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform | Laigo Bio, an Utrecht-based company pioneering novel and highly differentiated therapies using its proprietary SureTAC precision membrane protein degradation platform, has successfully raised €11.5 million in Seed financing. The funding rou... |
| 21.10.2025 | French startup Exeliom Biosciences boosts funding with €2.85 million to accelerate immunotherapy for cancer | Paris-based Exeliom Biosciences, a clinical-stage BioTech company developing new therapies in immuno-oncology and immuno-inflammation, today announced the completion of a €2.85 million extension to its Series A round, bringing the total Ser... |
| 20.07.2023 | Exeliom Biosciences Raises Additional €8M; Closes €24M Series A Round | Exeliom Biosciences, a Paris, and Dijon, France-based clinical-stage biopharmaceutical company, raised €8m in Series A extension funding. The round, which brought the total Series A amount to €24M, was led by CE-Ventures, the corporate vent... |
| 04.07.2023 | Exeliom Bioscience closes Series A financing at EUR 24 million | Paris, France-based clinical-stage biopharmaceutical company specialized in the development of microbiome-based immunotherapies with a mission to bring innovation to the treatment of inflammatory bowel diseases, cancer, and infectious disea... |
| 03.07.2023 | Paris-based Exeliom Biosciences completes final close of €24 million Series A to further progress its microbiome-based inmunotherapy | - |
| - | Exeliom Biosciences | “At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with inflammatory bowel diseases” |